Clinical trial • Phase III • Endocrinology

RO7795068 for Obesity

Phase III trial of RO7795068 for Obesity. 26 participants.

Overview

Trial Therapeutic Area
Endocrinology
Trial Disease
Obesity
Trial Stage
Phase III
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
26-01-2026
First CTIS Authorization Date
11-03-2026

Trial design

Phase III trial across 1 site in Netherlands.

Target Sample Size
26
Trial Duration For Participant
128

Recruitment

Planned Sample Size
26
Recruitment Window Months
4

Geography

Total Number Of Sites
1
Total Number Of Participants
26

Netherlands

Earliest CTIS Part Ii Submission Date
27-02-2026
Latest Decision Or Authorization Date
24-04-2026
Processing Time Days
56
Number Of Sites
1
Number Of Participants
26

Sites

Site Name
PRA Health Sciences
Department Name
Program Management
Contact Person Name
Salah Hadi
Contact Person Email
Salah.Hadi@iconplc.com

Sponsor

Primary sponsor

Full Name
F. Hoffmann-La Roche AG
Organisation Type
Pharmaceutical company
Country Of Registered Address
Switzerland

Contract research organisations

Name
PRA Health Sciences
Responsibilities
Program Management; listed as site contact in trialSites

Investigational products

Investigational Product Name
RO7795068
Modality
Small molecule

Related trials

Other published trials that may interest you.